1165 related articles for article (PubMed ID: 17070923)
1. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
2. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
3. Aspirin resistance and atherothrombotic disease.
Mason PJ; Jacobs AK; Freedman JE
J Am Coll Cardiol; 2005 Sep; 46(6):986-93. PubMed ID: 16168280
[TBL] [Abstract][Full Text] [Related]
4. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
5. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy and vascular disease: an update.
Buch MH; Prendergast BD; Storey RF
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):249-75. PubMed ID: 21303843
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Schulz C; Konrad I; Sauer S; Orschiedt L; Koellnberger M; Lorenz R; Walter U; Massberg S
Thromb Haemost; 2008 Jan; 99(1):190-5. PubMed ID: 18217153
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
10. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
11. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.
Pepine CJ
Ann Med; 2010; 42(1):19-35. PubMed ID: 20092398
[TBL] [Abstract][Full Text] [Related]
12. Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Ellahham S
South Med J; 2008 Mar; 101(3):273-83. PubMed ID: 18364658
[TBL] [Abstract][Full Text] [Related]
13. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
14. Statins and cardioprotection--more than just lipid lowering?
Ludman A; Venugopal V; Yellon DM; Hausenloy DJ
Pharmacol Ther; 2009 Apr; 122(1):30-43. PubMed ID: 19318042
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
16. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
Fisher M; Folland E
Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
19. Atherothrombosis and high-risk plaque: part I: evolving concepts.
Fuster V; Moreno PR; Fayad ZA; Corti R; Badimon JJ
J Am Coll Cardiol; 2005 Sep; 46(6):937-54. PubMed ID: 16168274
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation.
Abela GS
J Clin Lipidol; 2010; 4(3):156-64. PubMed ID: 21122648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
